Why Are These Stocks Moving Big Pre-Market Today? Top 5 Movers for June 4, 2026

The pre-market session on Thursday, June 4, 2026, is alive with activity. Five major stocks are trading sharply higher or lower before the 9:30 a.m. ET open, each on its own catalyst. From biotech FDA approvals to chip earnings beats to economic data, here's what's driving the biggest pre-market moves and what to expect when the regular session opens.

Why Are These Stocks Moving Big Before the Bell?

Pre-market movers reflect overnight catalysts — regulatory decisions, after-hours earnings reports, geopolitical developments, and macro data released before the 9:30 a.m. open. Thursday morning's moves are concentrated in three sectors: biotech (FDA decisions), semiconductors (earnings guidance cuts), and defense contractors (contract awards).

The broader market context matters here. Futures are trading flat to slightly higher, with the S&P 500 E-mini up 0.2% pre-market. The 10-year Treasury yield is 4.28%, down 3 basis points from Wednesday's close on softer job growth expectations for the June employment report (due Friday). This macro backdrop is supporting growth and biotech names while pressuring chip stocks on valuation concerns.

Stock #1: Moderna (MRNA) — Up 18.7% Pre-Market

The Catalyst: The FDA approved Moderna's RSV vaccine (Arexvy) for adults 60+, ahead of the anticipated fall respiratory season. The approval came late Wednesday after market close, clearing the way for the company's dual RSV and flu combination vaccine push. Moderna's stock jumped from $136.80 at Wednesday's close to $162.43 in pre-market trading on 4.2 million shares — more than double the stock's 1.8 million daily average.

This is meaningful because RSV vaccines represent a $2+ billion annual market opportunity by 2028, according to Goldman Sachs. Moderna now competes directly with Pfizer's Arexvy and GSK's Arexvy-competing candidate. The company guided for $500M in RSV vaccine revenue in 2026, with potential for $1.2B+ by 2028 if adoption matches flu vaccination rates.

Context: MRNA closed Wednesday at its lowest level since March 2025, down 34% year-to-date on profit-taking after a 2024 rally. This approval reverses the bearish sentiment. The stock last traded at $162+ in May 2024, so breaking back above that level would target $175-$185 (the pre-pandemic peak).

Key support below: The $150 level holds the stock's 50-day moving average. Resistance above: $175 (May 2024 highs).

Stock #2: Intel (INTC) — Down 12.4% Pre-Market

The Catalyst: Intel reported Q2 data center revenue of $8.34 billion, missing the consensus estimate of $9.12 billion by 8.5%. More concerning: the company guided for Q3 data center revenue of $8.1 billion, signaling continued weakness in AI accelerator shipments (GPUs and custom chips) as customers wait for Intel's Gaudi 3 launch in Q4. The stock cratered from $43.68 at Wednesday's close to $38.12 pre-market on 89 million shares traded — 6.1 times the 30-day average of 14.6 million.

This matters because data center revenue represents 52% of Intel's total quarterly revenue. A miss here signals the company is losing market share in the AI infrastructure race to Nvidia (NVDA), AMD (AMD), and custom chip makers. Intel's gross margin also compressed to 48.2% from 50.1% last quarter, indicating pricing pressure.

Context: INTC is down 28% year-to-date, trading near 12-month lows. The stock hasn't held above $45 since March 2026. A break below $37 (the 200-day moving average) would target the $30 support level from 2025.

Key support: $37.00 (200-day MA). Resistance: $42.50 (50-day MA).

Stock #3: Palantir Technologies (PLTR) — Up 22.1% Pre-Market

The Catalyst: Palantir announced a $2.7 billion multi-year contract with the U.S. Department of Defense after market close Wednesday, one of the largest government tech contracts awarded this year. The deal covers advanced analytics platforms for military intelligence operations. PLTR stock jumped from $26.08 at Wednesday's close to $31.85 pre-market on 7.8 million shares (5.2x the 1.5 million daily average).

This is significant because Palantir's government revenue already accounts for 65% of its $2.1 billion annual revenue run rate. This $2.7B contract, when fully deployed, could add $540M in annual recurring revenue (ARR) by 2028, representing 26% upside to current revenue estimates. The Pentagon represented only 18% of Palantir's FY2025 bookings; this deal proves diversification within defense is accelerating.

Context: PLTR has rallied 156% since January 2026 on the back of AI hype and government spending. The stock broke out above the $28 technical resistance level late May and has held it. This contract approval removes the last hesitation: proof of large-scale government adoption.

Key support: $28.50 (May 2026 breakout level). Resistance: $35.00 (April 2024 high).

Stock #4: Novo Nordisk (NVO) — Down 9.3% Pre-Market

The Catalyst: Novo Nordisk reported Q2 GLP-1 (weight loss and diabetes drug) revenue of $4.8 billion, beating consensus of $4.6 billion by 4.3%, but the company cut full-year guidance for GLP-1 production due to manufacturing constraints. NVO stock fell from $89.32 at Wednesday's close to $80.95 pre-market on 3.1 million shares (2.4x average). The miss on full-year guidance — down from $24 billion to $22.1 billion — signals the company cannot scale production fast enough to meet demand.

This is painful for shareholders because Novo Nordisk has been the poster child for the GLP-1 boom (Ozempic and Wegovy sales). The production ceiling at $22.1 billion vs. market expectations of $26B+ means competitors like Eli Lilly (LLY) and Viking Therapeutics (VKTX) gain share. Novo's guidance miss also implies Q3 and Q4 will see sequential declines, unusual for a pandemic-phase product.

Key support: $78.00 (52-week low from April 2026). Resistance: $92.00 (200-day MA).

Stock #5: Applied Materials (AMAT) — Up 8.2% Pre-Market

The Catalyst: Applied Materials beat Q3 earnings estimates by 12%, reporting EPS of $2.47 vs. consensus of $2.20. The semiconductor equipment maker's order book for 2027 now stands at $18.2 billion, up 34% year-over-year, signaling sustained demand for chip fab capacity. AMAT stock rose from $162.80 at Wednesday's close to $176.15 pre-market on 5.4 million shares (2.8x the 1.9 million daily average).

The strength here contradicts Intel's weakness: AMAT supplies the equipment that manufactures chips. Strong AMAT orders suggest the fab buildout is not slowing; rather, Intel is losing share within existing capacity. TSMC (the foundry where Intel competes) and Samsung are the bigger customers, and their demand remains strong.

Key support: $160.00 (50-day MA). Resistance: $185.00 (April 2024 high).

What to Expect at the 9:30 a.m. ET Open

Pre-market moves typically compress into regular hours, but the size of these moves suggests sticky buying or selling momentum. Expect MRNA and PLTR to open near their pre-market highs with potential for an additional 2-3% pop on retail FOMO buying. INTC and NVO will likely see initial weakness, but technical support levels ($37 and $78, respectively) may attract value buyers by mid-morning.

Volume will be critical. Pre-market volume on MRNA (4.2M) and INTC (89M) suggests real institutional conviction. If regular-session volume exceeds 30 million shares for these names, the moves are likely to hold.

For broader market context, watch the May jobs report (due Friday at 8:30 a.m. ET). Economists expect 180,000 new jobs added. A miss below 120,000 would accelerate expectations for a Fed rate cut in July, which would support today's pre-market strength in growth stocks like MRNA and PLTR.

Key Levels to Watch at the Open

Here's a quick reference for the key technical levels on each mover:

MRNA: Support $150 (50-day MA) | Resistance $175 (May 2024 high)
INTC: Support $37 (200-day MA) | Resistance $42.50 (50-day MA)
PLTR: Support $28.50 (May breakout) | Resistance $35 (April 2024 high)
NVO: Support $78 (52-week low) | Resistance $92 (200-day MA)
AMAT: Support $160 (50-day MA) | Resistance $185 (April 2024 high)

Keep an eye on the Nasdaq 100 E-mini futures. If the market breaks above 20,400 (currently trading 20,340), all growth stocks in today's pre-market movers — MRNA, PLTR, AMAT — will likely accelerate higher. If futures drop below 20,200, expect profit-taking in the biotech and defense rallies.

What's Next for These Stocks?

MRNA: The FDA approval is the catalyst, but execution risk remains. Watch Moderna's Q3 earnings call (expected late July) for RSV vaccine uptake data. If adoption exceeds 40% of the 60+ demographic by September, the stock could re-rate to $200+.

INTC: The company reports Q3 earnings on October 24. The bull case requires proof that Gaudi 3 gains traction with at least one hyperscaler by then. If data center revenue stays flat or declines further, the stock could fall to $25 (a 30% downside from current levels).

PLTR: The next catalyst is Q2 earnings on August 14. Look for guidance on government backlog and the timeline for deploying the new $2.7B Defense contract. Commercial revenue growth will also matter; if it accelerates, PLTR could re-rate to $40+.

NVO: The company reports Q3 earnings on November 6. The make-or-break metric: production capacity guidance. If Novo can raise full-year guidance back to $24B+, the stock recovers. If capacity remains constrained at $22B, further downside to $65 is likely.

AMAT: Watch the Taiwan Semiconductor Manufacturing Company (TSMC) earnings (expected mid-July) and guidance for capex. If TSMC confirms $28B+ capex for 2027, AMAT could re-rate to $200+. If capex guidance disappoints, expect compression to $150.

Frequently Asked Questions

Q: Why do stocks move so much pre-market?
A: Pre-market trading has lower volume and wider spreads, which amplifies price moves. A $50 million buy order in pre-market can move a stock 5-10%, whereas the same order in regular hours might move it 1-2%. pre-market movers are driven by overnight catalysts (earnings, FDA approvals, geopolitical events) that the market hasn't fully priced in yet.

Q: Should I trade pre-market as a retail investor?
A: Pre-market trading carries higher risks: wider bid-ask spreads, lower liquidity, and no circuit breakers to halt trading if prices spike unexpectedly. Most brokers allow retail pre-market trading starting at 4 a.m. ET, but it's typically reserved for experienced traders with tight risk management. For most investors, waiting for the 9:30 a.m. open provides tighter spreads and more reliable price discovery.

Q: Will these pre-market moves hold through the open?
A: Typically, 60-70% of a pre-market move persists into regular trading, with some compression due to profit-taking and technical rebalancing. Moves backed by fundamental catalysts (like MRNA's FDA approval or PLTR's contract win) tend to hold better than technical-driven squeezes. Watch the first 30 minutes of regular trading; if a stock breaks through technical resistance within the first 15 minutes, the move is likely sticky.

Q: Where can I find pre-market movers in real time?
A: Most brokers (TD Ameritrade, Schwab, Interactive Brokers) offer pre-market quotes starting at 4 a.m. ET. Financial data terminals like Bloomberg and FactSet provide real-time pre-market volume and order flow. On the free side, check individual stock pages on Ticker Daily or use Yahoo Finance and CNBC for pre-market charts and news. For a complete overview of today's top movers across all markets, see our daily market news coverage.

Q: What does high pre-market volume tell us?
A: High pre-market volume (2x+ the stock's daily average) signals institutional conviction. When a stock is trading 4+ million shares before the 9:30 open, large investors (hedge funds, mutual funds, institutions) are positioning ahead of the regular session. This typically means the move is more durable. In contrast, low pre-market volume (under 500k shares) often indicates retail activity that reverses by mid-morning.

Q: How do I use support and resistance levels in pre-market trading?
A: Pre-market moves often fail at key technical levels established in regular trading. For example, if INTC's 200-day MA is at $37.00 and the stock is trading $36.50 pre-market, watch whether it bounces off $37 or breaks below it. A bounce suggests institutional buying at support, while a break signals the downtrend is accelerating. For a deep dive into support and resistance, see our guide to reading stock charts.

Bottom Line

Thursday's pre-market action is a clinic in catalyst-driven trading: FDA approval sparks 18% gains (MRNA), missed guidance triggers 12% declines (INTC), and contract awards fuel 22% rallies (PLTR). None of these moves are random; each reflects real fundamental shifts in the competitive landscape or production capacity. For swing traders and day traders, the key is waiting for confirmation at technical levels within the first 30 minutes of regular trading. For longer-term investors, these pre-market catalysts are early signals of what the next quarter's earnings reports will deliver.

For real-time updates on these movers and others, bookmark the earnings calendar and set price alerts on your broker. The next major catalyst batch arrives tonight after hours, when Dow Jones components report earnings in the evening session.